Lipid intervention in diabetes, metabolic syndrome and beyond

Int J Cardiol. 2018 Oct 1:268:200-201. doi: 10.1016/j.ijcard.2018.05.035.

Authors

Carl J Lavie¹, Richard V Milani², James H O'Keefe³

Affiliations

¹ John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA. Electronic address: clavie@ochsner.org.
² John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.
³ St. Luke's Mid America Heart Institute, Kansas City, MO, USA.

PMID: 30041786
DOI: 10.1016/j.ijcard.2018.05.035

No abstract available

Publication types

Editorial
Comment

MeSH terms

Diabetes Mellitus, Type 2*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Metabolic Syndrome*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids